Zomedica Q3 revenue up 31% to record $6.3M; net loss narrows to $0.3M; NYSE listing deficiency

Zomedica Corp.

2023-Q3 EPS reported -$0.01 revenue$17,849,000

Revenue of $6.3M, up 31% YoY; gross margin 69%, up from 67% sequential.
Net loss narrowed to $0.3M ($0.001/share) from $5.8M ($0.005/share) a year ago.
Non-GAAP EBITDA loss $0.3M vs $3.0M loss; adjusted non-GAAP EBITDA profit $0.3M.
Liquidity $118M; completed acquisitions of SMP (VetGuardian) and Qorvo Biotechnologies.
NYSE American notified of low share price deficiency; 30-day avg <$0.20; company plans cure.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Zomedica Corp. reported the quarter ended September 30, 2023 results: revenue $6.3 million.

Period: the quarter ended September 30, 2023
Revenue: $6.3 million
Result: reported results

Exact text from the filing

EX-99.1 (PRESS RELEASE) --- EX-99.1 2 zom_ex991.htm PRESS RELEASE zom_ex991.htm EXHIBIT 99.1 Zomedica Announces Record Third Quarter 2023 Financial Results: Revenue up 31% to $6.3 Million; 69% Gross Margin, and $118 Million in Liquidity, while Making Strategic Acquisitions of Structured Monitoring Products and Qorvo Biotechnologies ANN ARBOR, MI / ACCESSWIRE /

View on SEC.gov

Browse all earnings releases →

Zomedica Corp. filing history →

Source: SEC EDGAR

accession 0001654954-23-014163

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.